GSE193964 MI-1 Kasumi-1 1 v 0 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE193964_MI-1_Kasumi-1_1_v_0_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE193964_MI-1_Kasumi-1_1_v_0_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE193964_MI-1_Kasumi-1_1_v_0_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE193964_MI-1_Kasumi-1_1_v_0_human_up.

Results found

Linked to

 

Label

Description

 

Gene

NR2F2 antisense RNA 1

Gene

ELOVL2 antisense RNA 1

Gene

GPR107 adjacent cis regulating lncRNA

Gene

RNA, 7SL, cytoplasmic 596, pseudogene

Gene

EPN2 antisense RNA 1

Gene

UCHL1 divergent transcript

Gene

uncharacterized LOC101928557

Gene

RNA, 7SL, cytoplasmic 517, pseudogene

Gene

killer cell lectin like receptor F1

Gene

fibronectin type III domain containing 4

  • Gene

    NR2F2 antisense RNA 1


  • Gene

    ELOVL2 antisense RNA 1


  • Gene

    GPR107 adjacent cis regulating lncRNA


  • Gene

    RNA, 7SL, cytoplasmic 596, pseudogene


  • Gene

    EPN2 antisense RNA 1


  • Gene

    UCHL1 divergent transcript


  • Gene

    uncharacterized LOC101928557


  • Gene

    RNA, 7SL, cytoplasmic 517, pseudogene


  • Gene

    killer cell lectin like receptor F1


  • Gene

    fibronectin type III domain containing 4

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.